An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Inclusion Criteria prior to Surgery: * Suspected or histologically confirmed Stage IIA to IIIB NSCLC with disease that is considered resectable * Must be deemed eligible for complete resection and must agree to undergo standard of care surgery for complete resection of NSCLC * Treatment naive (no previous systemic treatment) Inclusion Criteria prior to Treatment Randomization: * Must have undergone complete surgical resection of their Stage IIA to IIIB NSCLC * Must have adequately recovered from surgery at the time of randomization * Minimal residual disease (MRD) positive results as detected by ctDNA Exclusion Criteria prior to Surgery: * Participants with known EGFR mutations which are sensitive to available targeted inhibitor therapy (Prior to treatment randomization in select sites) * Active, known or suspected autoimmune disease * Participants with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization Exclusion Criteria prior to Treatment Randomization: * Must continue to meet Exclusion Criteria prior to Surgery * Must have no evidence of metastatic disease after surgery * Received a live/attenuated vaccine within 30 days of first treatment Other protocol defined inclusion/exclusion criteria apply